Liver cancer drug trial halted early – what we know so far
NCT ID NCT06851104
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a drug called cadonilimab in people with liver cancer who had surgery to remove their tumor but were at high risk of the cancer returning. The goal was to see if the drug could help keep the cancer away. The trial was stopped early, so the full results are not yet known.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cadonilimab (AK104)
What this could lead to
If successful, this could point toward a treatment that lowers the chance of liver cancer returning after surgery.
What could go wrong
The study was terminated early, so data is limited. It is a small phase 2 trial, and the drug may cause side effects like immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, 530021, China